Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist to treat congenital hyperinsulinism, which is in phase 1 clinical trial; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase 1 clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.
IPO Year: 2018
Exchange: NASDAQ
Website: crinetics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2026 | $67.00 | Neutral → Buy | Goldman |
| 7/10/2025 | $36.00 | Neutral | Goldman |
| 3/25/2025 | $60.00 | Buy | Stifel |
| 2/11/2025 | Buy | TD Cowen | |
| 2/4/2025 | Peer Perform | Wolfe Research | |
| 1/22/2025 | $55.00 | Hold → Buy | Jefferies |
| 3/6/2024 | $68.00 | Buy | Citigroup |
| 1/16/2024 | $50.00 | Overweight | Morgan Stanley |
| 12/21/2023 | $35.00 | Hold | Jefferies |
| 11/20/2023 | $35.00 | Overweight | JP Morgan |
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Goldman upgraded Crinetics Pharmaceuticals from Neutral to Buy and set a new price target of $67.00
Goldman initiated coverage of Crinetics Pharmaceuticals with a rating of Neutral and set a new price target of $36.00
Stifel initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $60.00
TD Cowen initiated coverage of Crinetics Pharmaceuticals with a rating of Buy
Wolfe Research initiated coverage of Crinetics Pharmaceuticals with a rating of Peer Perform
Jefferies upgraded Crinetics Pharmaceuticals from Hold to Buy and set a new price target of $55.00
Citigroup initiated coverage of Crinetics Pharmaceuticals with a rating of Buy and set a new price target of $68.00
Morgan Stanley initiated coverage of Crinetics Pharmaceuticals with a rating of Overweight and set a new price target of $50.00
Jefferies initiated coverage of Crinetics Pharmaceuticals with a rating of Hold and set a new price target of $35.00
JP Morgan resumed coverage of Crinetics Pharmaceuticals with a rating of Overweight and set a new price target of $35.00
Fastest customizable press release news feed in the world
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins
Oral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing's syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate atumelnant, will be presented at t
SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY. Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on dis
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026. "We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Pa
PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly
Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business & Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline. Ms. Dear
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 7 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:173777518 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that par
SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. "The submission of our MAA for Palsonify in Brazil represents another important global milestone for this important therapy," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "Once-daily, oral Palsonify is redefining the treatment paradigm as the next generati
PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-relate
SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the following two upcoming investor conferences: TD Cowen 46th Annual Health Care Conference, Boston, MA Fireside chat on Wednesday, March 4, 2026 at 1:50 p.m. Eastern TimeWebcast link HERE Management will be available for 1x1 meetings with investors on Wednesday, March 4, 2026 Leerink Annual Global Healthcare Conference, Miami, FL Management will be available for 1x1 meetings with investors on Wednesday, March 11, 2026 The live and archived webcast will be accessible on the Events & Presentations page in the Investors section of the C
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
10-Q - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
DEF 14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
Live finance-specific insights
PALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026. "We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Pa
SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 7 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:173777518 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that par
SAN DIEGO, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, February 26 at 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 646-844-6383Access Code: 027322 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection,
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Successfully Reduce Glucocorticoid Dose to Physiologic Replacement Levels Atumelnant's Favorable Benefit/Risk Profile Was Maintained in Cohort 4 and Open-Label Extension of Phase 2 CAH Study With No Hepatic Transaminase Adverse Events Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cr
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. Conference Call and Webcast DetailsManagement will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible
PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the third quarter ended September 30, 2025. "September 25, 2025 was a historic day for Crinetics with the approva
SAN DIEGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, November 6 at 4:30 p.m. ET Domestic:1 833-470-1428International:1 646-844-6383Access Code:166837 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended tha
Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 trials where PALSONIFY was well tolerated and resulted in rapid, durable, and consistent biochemical control and reduced symptom burden Launch of lead product PALSONIFY marks a pivotal milestone for Crinetics as the premier endocrine-focused global pharmaceutical company Investor call to be held today at 6:00 pm ET SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFYTM
Regulatory Interactions and Commercial, Medical and Corporate Preparations On-Track for PALSONIFY™ (paltusotine) New Drug Application with September 25, 2025 PDUFA Date Continued Progress on the Global Development Program for Atumelnant Across Multiple Trials, Including the BALANCE-CAH Phase 2/3 Study for the Treatment of Children with Congenital Adrenal Hyperplasia Expected to Initiate this Year $1.2B in Cash, Cash Equivalents, and Investment Securities as of June 30, 2025 Anticipated to Provide Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, August 7 @ 4:30 p.m. ET Domestic: 1 833-470-1428International: 1 404-975-4839Access Code: 899803 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommen
Live Leadership Updates
Everyday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins
Ms. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business & Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline. Ms. Dear
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Tobin "Toby" Schilke as chief financial officer, effective February 28, 2025. Mr. Schilke is a seasoned biopharma executive with over 25 years of global pharmaceutical experience. In prior roles, his leadership was instrumental in transforming several biotech companies from R&D-focused entities into fully integrated commercial organizations. "I am excited to welcome Toby to our senior leadership team during this transformational stage of our evolution into a global pharmaceutical company," said Scott Struthers, Ph.D., founder and chief executive officer of Crineti
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company's commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company's deep, innovative pipeline of candidates. "Isabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy," said Scott Struthers, Ph.D
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced the appointment of Robert M. Cuddihy, M.D., as senior vice president of Medical Affairs. Dr. Cuddihy is a board-certified physician in endocrinology, diabetes and metabolism with more than 30 years of experience spanning clinical practice and pharmaceutical industry medical affairs. "Dr. Cuddihy's wealth of knowledge and experience both as a practicing physician in endocrinology and working within the pharmaceutical industry is an invaluable addition to our talented scientific leadership team," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "As we forg
- Series A led by Frazier Life Sciences, 5AM Ventures and DCVC Bio, bringing total raised to date to $82.5 million - Paul Grayson joins as Chief Executive Officer, bringing additional expertise in business strategy, oncology, and G-protein coupled receptor biology - Radionetics expands board of directors with the appointment of Eric Shiozaki, Ph.D., Partner at DCVC Bio Radionetics Oncology, Inc., a clinical stage radiopharmaceutical company focused on the discovery and development of novel agents for the treatment of a wide range of oncology indications, announces the completion of a $52.5 million Series A financing. The round was led by Frazier Life Sciences, 5AM Ventures, and new invest
Radionetics adds key expertise in radiopharmaceutical drug development as company expects to file three INDs in 2023 and 2024 Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, is pleased to announce the appointment of Istvan Molnar, M.D. as Chief Medical Officer. Dr. Molnar is an industry veteran bringing 15 years of experience in oncology clinical development, including significant expertise in radiopharmaceutical drug development. Dr. Molnar has a broad background in oncology and radiopharmaceutical drug development spanning early- to late-stage projects with exten
Paltusotine's Phase 3 PATHFNDR-1 trial in acromegaly fully enrolled and on track for topline data in Q3 2023 Paltusotine lowered and maintained IGF-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly participating in the ACROBAT Advance Long-term Extension Study SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today reported financial results for the third quarter ended September 30, 2022. "This has been yet another successful quarter of executing our strategy to build a leading endocrinology company by advancing our clinical pipeline of internally discovered drug candidates and
SAN DIEGO, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer. Dr. Pizzuti is a board-certified physician with more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigilance, and medical and regulatory affairs. "Dr. Pizzuti's expertise in working with global regulators to safely and effectively progress multiple programs through development and ultimately commercialization will serve us well as our extensive pipeline of internally discovered drug candidates advances," said Scott Struthers, Ph.D., founder and chief executive officer of Crinet
- Radionetics adds expert in GMP radiopharmaceutical manufacturing as company expects to file three INDs in the next two years - Company more than doubles employees to 20 within one year Radionetics Oncology, a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications, announced today the appointment of Umesh Gangadharmath, Ph.D. as Senior Vice President, Technical Operations. Dr. Gangadharmath brings more than 16 years of experience in researching and developing novel radiopharmaceuticals. His breadth of expertise spans preclinical development —supporting chemistry, manufacturing, and controls (CMC
This live feed shows all institutional transactions in real time.
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13D/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
SC 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)